News & Press Releases Swedish

Scandinavian ChemoTechs dotterbolag Vetiqure har fått preliminärt positivt behandlingsresultat

Preliminärt resultat av första TSE-behandlingen på Evidensia Specialistdjursjukhuset Helsingborg pekar på ett resultat som är bättre än förväntat.

Read more

Scandinavian ChemoTech har säkrat CE-märkta elektroder för djupt sittande tumörer

Efter framgångsrika sluttester har Scandinavian ChemoTech, tillsammans med sin samarbetspartner inom elektrodteknologi, utvecklat CE-märkta behandlings-kit för djupt sittande tumörer.

Read more

Scandinavian ChemoTechs COO avslutar sitt uppdrag

Scandinavian ChemoTechs COO Urban Widen avslutar sitt interimsuppdrag efter ett väl genomfört arbete.

Read more

News & Press Releases English

Scandinavian ChemoTech's subsidiary Vetiqure has received a preliminary positive treatment result

Preliminary results of the first TSE treatment at Evidensia Specialistdjursjukhuset Helsingborg point to a result that is better than expected.

Read more

Scandinavian ChemoTech has secured CE-marked electrodes for deep-seated tumours

Following successful final tests Scandinavian ChemoTech, along with its partner in electrode technology, has developed CE-marked treatment kits for deep-seated tumours.

Read more

Scandinavian ChemoTech's COO completes his assignment

Scandinavian ChemoTech's COO Urban Widen ends his interim assignment after a job well done.

Read more

ChemoTech Videos

Nydanande TSE-teknologi ökar den lokala effekten av cellgiftbehandling

ChemoTech presents for its upcoming Annual General meeting 24 May 2021. Spoken language is Swedish but the presentation is in English.

ChemoTech answers questions from the shareholders; Part 1 (Swedish)

CEO Mohan Frick presenting at Erik Penser Bank Bolagsdag (Swedish)

Erik Penser Bank interview with CEO Mohan Frick (Swedish)

Company Presentation of the Q3 report (Swedish) 11th of November 2020

Company Presentation (Swedish) 27th of October 2020

Videos from 2019

Share Day in Gothenburg, November 4 2019 (Swedish)

Videos from 2018

Share analysis ChemoTech Q2 2018 (Swedish)

Share Day in Malmö on May 22, 2018 (Swedish)

Our foundation

Our profound knowledge in Electroporation forms the starting point for the company’s existing product and R&D projects : IQwave™ specially desinged for both TSE- Tumour Specific Electroporation and the first generation electrochemotherapy for the treatment of a range of different types of tumours.

Our research focus

Our aim is to document the effects of elctrochemotherapy for pain management for cancer patients, an area with significant unmet medical need.